HALOZYME THERAPEUTICS, INC. (HALO) Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Halozyme Therapeutics, Inc. NASDAQ:HALO Healthcare · Biotechnology
Mkt Cap $14.86B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order
businesswire.com • 5d ago Press Release
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Halozyme Therapeutics announced it will release third quarter 2026 financial and operating results on Thursday, November 5, 2026, after the market close.
A conference call to discuss the results will be held the same day at 1:30pm PT / 4:30pm ET, with a live webcast and replay available on the company's website.
The release contains no financial figures or operational news -- it is purely an earnings-date and webcast scheduling notice.
• 10d ago AI analysis › Press Release
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
Russell Investments Canada announced October and November monthly cash distributions for its ETF Series and ETFs, with the Russell Investments Fallen Angels ETF (TSX: HALO) paying $0.1000 per unit.
For HALO, the October record date is October 21, 2026 with payment on October 26, 2026, and the November record date is November 19, 2026 with payment on November 25, 2026.
This is a routine distribution schedule announcement with no change to payout policy; the release notes distributions are not guaranteed and subject to change or elimination.
• 19d ago AI analysis › Press Release
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
prnewswire.com • 25d ago Press Release ⚠ 1
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Halozyme expanded its global collaboration and license agreement with argenx to develop subcutaneous formulations for two additional exclusive targets using its ENHANZE drug delivery technology.
The expansion increases argenx's exclusive access to ENHANZE from six to eight targets, building on the successful development of VYVGART Hytrulo for myasthenia gravis and CIDP.
Halozyme is eligible for milestone payments and royalties on net sales of products using ENHANZE under the expanded agreement, though no specific financial terms or upfront payment were disclosed.
• 26d ago AI analysis › Press Release
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Therapeutics appointed James "Jim" Daly to its Board of Directors, a biopharma commercial executive with over three decades of experience.
Daly previously served on Halozyme's board and held senior commercial roles at Incyte, Amgen, and GlaxoSmithKline; he currently sits on the boards of Acadia, Madrigal, and Cytokinetics.
The appointment is a routine governance update with no change to strategy or management, though Daly's commercial launch experience supports Halozyme's expanding ENHANZE, Hypercon, and Aerocon partnerships.
• 1mo ago AI analysis › Press Release ● Major ⚠ 4
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme priced an upsized $1.3 billion private offering of 1.50% convertible senior notes due October 1, 2033, increased from the previously announced $1.05 billion, with a 13-day option for initial purchasers to buy up to $200 million more. The deal is expected to close September 22, 2026.
The notes carry an initial conversion price of approximately $139.84 per share, a 27.5% premium to the $109.68 September 17 close, and concurrent capped call transactions with a $208.39 cap price (roughly 90% premium) are designed to reduce potential dilution above the conversion price.
Expected net proceeds are approximately $1.275 billion (up to $1.471 billion if the option is exercised in full), with $162.5 million funding the capped calls and roughly $217.0 million and $435.5 million used to repurchase $151.7 million and $220.0 million principal amounts of the 2027 and 2028 convertible notes, respectively. The remainder is earmarked for general corporate purposes, including working capital, capital expenditures, and potential acquisitions.
• 1mo ago AI analysis › Press Release ⚠ 4
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics intends to offer $1.05 billion of convertible senior notes due 2033 in a Rule 144A private placement to qualified institutional buyers, with a 13-day option for initial purchasers to buy up to an additional $150 million of notes.
Proceeds are earmarked to fund capped call transactions designed to reduce conversion dilution and to repurchase portions of the outstanding 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 for cash, with the remainder for general corporate purposes including working capital, capital expenditures and potential acquisitions.
The interest rate and initial conversion rate will be set at pricing, and the senior unsecured notes mature October 1, 2033, with conversions settled in cash and, at the company's election, shares.
Structurally this is liability management — refinancing the 2027 and 2028 converts while capping dilution — rather than a straight dilutive equity raise, though hedging flows by option counterparties around pricing could move HALO shares.
• 1mo ago AI analysis › Press Release
Halozyme to Participate at Upcoming Investor Conferences
Halozyme management will participate in three healthcare investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference on September 9, the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16.
CEO Dr. Helen Torley and CFO Darren Snellgrove will host fireside chats and 1x1 meetings at each event, with live audio webcasts available on the company's Investor Relations site and replays archived for 90 days.
The release carries no new financial, clinical, or strategic disclosure -- it is a routine IR scheduling notice, with the remainder of the text drawn from standard company boilerplate on ENHANZE, Hypercon, and its auto-injector portfolio.
• 1mo ago AI analysis › Press Release
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors, adding over 20 years of operational and manufacturing leadership experience in the biotechnology and pharmaceutical industries.
Ms. Appelhans currently serves as CEO of COUR Pharmaceuticals and previously held senior roles at Rubius Therapeutics and Novartis, where she led the gene therapy unit including the development of Zolgensma.
CEO Dr. Helen Torley noted that Appelhans' expertise in global operations aligns with the company's strategy to scale the ENHANZE platform and advance the Hypercon and Surf Bio initiatives.
• 2mo ago AI analysis › Press Release
Sagtec Officially Launches HALO AI and Secures US$3 Million Purchase Order for 1,500 AI Food-Serving Robots from Dubai Distributor
globenewswire.com • 2mo ago Press Release ● Critical ⚠ 2
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme delivered record Q2 2026 results with total revenue rising 48% year-over-year to $481 million, driven by a 50% increase in royalty revenue to $308 million.
Based on the strong performance, the company raised its full-year 2026 guidance, now expecting total revenue of $1.835 billion to $1.910 billion and Non-GAAP diluted EPS of $8.65 to $9.00.
The company also returned significant capital to shareholders, repurchasing $333 million of stock in Q2 at an average price of $69.30, and signed five new collaboration agreements year-to-date.
• 2mo ago AI analysis › Press Release
Halozyme to Report Second Quarter 2026 Financial and Operating Results
Halozyme Therapeutics announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading.
The company will host a conference call the same day at 4:30 p.m. ET to discuss the results, accessible via webcast or pre-registration.
Halozyme focuses on drug delivery technologies, including ENHANZE and Hypercon, and partners with major pharmaceutical companies.
• 3mo ago AI analysis › Press Release
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Halozyme Therapeutics entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, a mutant calreticulin-targeted antibody, using Halozyme's ENHANZE technology.
The terms include an upfront payment to Halozyme, eligibility for milestone payments, and royalties on future net sales, with Incyte having the option to nominate up to two additional targets.
CEO Dr. Helen Torley emphasized that the deal underscores the momentum of ENHANZE technology across high-value therapeutic areas and expands the company's portfolio of partnered programs.
• 3mo ago AI analysis › Press Release
Halozyme Appoints David Ramsay as President Drug Delivery
Halozyme Therapeutics appointed David Ramsay as President of Drug Delivery, a newly created role effective June 30, 2026.
Mr. Ramsay, a former interim CFO and company veteran, will assume an enterprise-wide mandate to drive the growth of Halozyme's drug delivery technologies and report directly to CEO Helen Torley.
The appointment highlights the company's focus on expanding its technology portfolio and partnerships during a period described as one of unprecedented growth.
• 4mo ago AI analysis › Press Release
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme confirms that the newly released CMS proposed rule for the Medicare Drug Price Negotiation Program will have zero to minimal impact on its royalty revenue through at least 2035.
The company attributes this favorable outlook to the preservation of orphan drug protections and specific provisions regarding biosimilar entry in the proposed rule under the One Big Beautiful Bill Act.
CEO Dr. Helen Torley stated that there is also no projected impact on the company's ability to execute new ENHANZE partnership agreements, as competitive differentiation remains the primary driver for partner adoption.
• 4mo ago AI analysis › Press Release ● Critical
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
globenewswire.com • 5mo ago Press Release ● Critical
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics reported Q1 2026 total revenue of $376.7 million, a 42% increase from $264.9 million in Q1 2025, driven by strong royalty revenue growth and increased product sales.
The company announced a new $1 billion share repurchase program, with an expectation to buy back at least $400 million in 2026, reflecting confidence in its business and strong cash generation.
Halozyme reaffirmed its 2026 financial guidance, projecting total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, and non-GAAP diluted earnings per share of $7.75 to $8.25.
The company also highlighted several recent partnerships and positive clinical trial results, including the FDA approval of VYVGART Hytrulo for all serotypes of generalized myasthenia gravis and positive Phase 3 data for VYVGART in ocular myasthenia gravis.
• 5mo ago AI analysis › Press Release
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Halozyme entered a global licensing agreement with GSK to utilize its ENHANZE drug delivery technology for subcutaneous formulations of oncology targets, including antibody drug conjugates (ADCs).
The collaboration includes an upfront payment, future milestones, and royalties on net sales, marking the first time ENHANZE has been applied to ADCs.
Management projects the first clinical trial under this partnership to begin in 2026, potentially expanding Halozyme's high-margin royalty revenue into a rapidly growing therapeutic class.
• 5mo ago AI analysis › Press Release
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Halozyme Therapeutics entered into a global license agreement with Oruka Therapeutics to apply Hypercon technology to ORKA-001, a treatment for psoriasis and related inflammatory diseases.
The deal grants Oruka exclusive rights for IL-23p19 in psoriatic disease and an option for one additional target, with Halozyme receiving an upfront payment, milestones, and mid-single digit royalties.
CEO Dr. Helen Torley highlighted that this is the second Hypercon collaboration this year, further validating the technology's applicability.
• 5mo ago AI analysis › Press Release ● Major
Halozyme to Report First Quarter 2026 Financial and Operating Results
prnewswire.com • 6mo ago Press Release
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
prnewswire.com • 6mo ago Press Release ● Major
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
globenewswire.com • 6mo ago Press Release
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
prnewswire.com • 6mo ago 
